Articles

Personal perspective: living with hepatitis C

28th July 2015

Personal perspective: living with hepatitis C

On #WorldHepatitisDay we highlight a personal account from a woman in the US diagnosed with hepatitis C and how this has impacted her life.When I was diagnosed ...I am a... Read more

Can treatment as prevention work for hepatitis C?

27th July 2015

Can treatment as prevention work for hepatitis C?David Rowlands

The advent of better drugs has helped increase interest in treatment as prevention for hepatitis C (HCV). With tomorrow's #WorldHepatitisDay drawing global attention to the condition, David Rowlands examines the... Read more

An empowered patient means an empowered Europe

24th July 2015

An empowered patient means an empowered EuropeCynthia Bonsignore

Young Europeans are working together to suggest ways to manage health that will result in benefits to citizens and budgets. As more of us take control of our own wellbeing,... Read more

Major overhaul of Cancer Drugs Fund proposed

22nd July 2015

Major overhaul of Cancer Drugs Fund proposedAndrew McConaghie

NHS England plans to introduce conditional NICE approval and real world data to make Cancer Drugs Fund sustainable. Andrew McConaghie reports.The Cancer Drugs Fund (CDF) is to undergo a major... Read more

News

Teva's $40bn Allergan acquisition adds twist to merger drama

28th July 2015

Teva's $40bn Allergan acquisition adds twist to merger dramaKevin Grogan

The merger merry-go-round continues to spin, although the three-way drama involving Teva Pharmaceutical Industries, Mylan and Perrigo has taken an unexpected turn, with the Israeli firm buying the generics unit... Read more

Europe fast tracks rival myeloma drugs from Takeda, Abbvie and BMS

27th July 2015

Europe fast tracks rival myeloma drugs from Takeda, Abbvie and BMSAndrew McConaghie

Two rival treatments for multiple myeloma have been granted 'accelerated assessment' by Europe's medicines regulator.The EMA's accelerated assessment is similar to the FDA's Breakthrough Therapy Designation, being reserved for medicines... Read more

Malaria vaccine and Sanofi's Praluent lead CHMP opinions

27th July 2015

Malaria vaccine and Sanofi's Praluent lead CHMP opinionsKevin Grogan

The latest set of recommendations by European Medicines Agency are dominated by positive opinions for the world's first malaria vaccine from GlaxoSmithKline and Sanofi/Regeneron's closely-watched injectable cholesterol-lowering treatment.First up, the... Read more

Prostate cancer breakthrough must wait for publication, says NHS Engla…

24th July 2015

Prostate cancer breakthrough must wait for publication, says NHS EnglandAndrew McConaghie

Groundbreaking, low-cost treatment which dramatically extends the lives of prostate cancer patients won't be recommended until after trial results are published in a peer reviewed journal, NHS England has said.Earlier... Read more

Audio & Video

Available on demand: Changing behaviour:…

BrightTALK holding slide 4 22June

 

Understanding your customers is fundamental to effective communication. Current segmentation strategies draw on ever more detailed information... View more

Available on demand: Effectively using r…

Zephyr-Webinar-Holding-Slide-2

 

Life sciences companies need to make better use of the insights that real-world data (RWD) can provide in order to improve market... View more

Available on demand: Exclusive debate/we…

Ashfield-PP-HS1

 

The way that physicians want and need to consume information has changed dramatically over recent years and continues to evolve rapidly. Working in... View more

Being Patient-centric is being Family-ce…

 

Cancer survivor and patient opinion leader Andrew Schorr and his wife Esther Schorr discuss how families should be involved in decision-making around care for patients.... View more

White Papers

Optimising patient outcomes through phys…

Optimising patient outcomes through physician educationDr James Quekett

Physician education is undergoing a massive change as the volume of advances in therapies and practices increases and the use of digital channels facilitates new forms of scientific exchange. This white... View info

Is pharma brand marketing dead?

Is pharma brand marketing dead?Mark Sales, Fabrice Bourg & Richard Goosey

This comprehensive supplement brings together a series of articles, insights and discussions produced by Kantar Health in order to help stimulate debate and fresh thinking about the future of pharmaceutical... View info

Improved health and wellbeing in COPD

Improved health and wellbeing in COPDAna Maria Arboleda, Clare Maloney & Prof John Weinman

Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating disorder, which, as it progresses, places a significant burden on individuals and those caring for them. This is not only... View info

Computer Gaming: The Future of Decision-…

Computer Gaming: The Future of Decision-Making for Life Sciences?

How can life science brands identify winning strategic decisions when there are so many variables to consider? One route is via 'road-testing' decisions ahead of sign-off under computer game simulated... View info

Further News & Articles

Boehringer boost as MHRA confirms benefit of stroke drug alteplase

Boehringer Ingelheim (BI) is celebrating after an independent evaluation in the UK has reconfirmed that the bene... Read more

News

Cancer Drugs Fund to change – but will the data revolution arrive in time?

NHS England has confirmed that it wants to overhaul the Cancer Drugs Fund (CDF), which, it says, will stop some ... Read more

News

Independent US institute to investigate drug pricing

The debate over the cost of new medicinal products will soon have a new voice, in the form of a non-profit group... Read more

News

Mixed results for Alzheimer’s drugs hit Biogen

Three companies unveiled data from major trials in Alzheimer's disease yesterday, with Biogen, Lilly and Roche a... Read more

News

Novartis bullish on Entresto launch, but not until 2016

The prospects for Novartis' new heart failure drug Entresto dominated discussions during its second-quarter resu... Read more

News

Motif antibiotic secures special status from FDA

UK company Motif Bio has gained an FDA special status for its pipeline novel antibiotic, which will help secu... Read more

News